Samsung Bioepis’ Pembrolizumab biosimilar SB27 meets phase 1 PK endpoints
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Subscribe To Our Newsletter & Stay Updated